GlassScriptPhysician profile
Lauri I An
NPI 1134168891
$3,927.91
in general payments reported to CMS, 2019-2025
20 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $1,309 · 2021: $832 · 2022: $354 · 2023: $46.88 · 2024: $299 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $863.03 | 2019-2023 | |
| Amgen INC. | $792.49 | 2019-2024 | Prolia, Evenity |
| Abbvie INC. | $777.18 | 2019-2024 | Linzess |
| Ardelyx, INC. | $220.22 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $154.92 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $150.06 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.49 | 2019 | |
| Phathom Pharmaceuticals, INC. | $110.39 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $106.51 | 2019-2021 | |
| Novo Nordisk INC | $101.56 | 2020 | |
| Pfizer INC. | $92.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.36 | 2020-2025 | Jardiance |
| Allergan, INC. | $82.55 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $74.68 | 2024-2025 | Zenpep |
| Scilex Pharmaceuticals INC. | $38.57 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $35.69 | 2020 | |
| Shire North American Group INC | $34.71 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.35 | 2019-2020 | |
| Glaxosmithkline, LLC. | $26.26 | 2020-2021 | |
| Genentech USA, INC. | $14.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauri An listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.